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1  | INTRODUC TION
The serious health consequences of diabetes are illustrated by the 
statistic that diabetes causes 1 death every 6 seconds and consti-
tutes approximately 15% of human mortality worldwide.1 Obesity 
is the strongest risk factor for the development of type 2 diabetes, 
accounting for approximately 80% of the risk.2 Obesity is defined 
as a body mass index (BMI) greater than 30 kg m2 and arises when 
energy intake exceeds energy expenditure. The number of obese 
and overweight adults has almost tripled worldwide since 1975, with 
more than 2.1 billion adults now meeting criteria.3 A more striking 
increase in average body weight is evident in children. From 1975 to 
2016, the proportion of obese children and adolescents increased 
from less than 1% to 5.6% in boys and 7.8% in girls.3
A typical strategy to treat obesity and type 2 diabetes is life-
style modification, including reducing caloric intake and increasing 
physical exercise. However, this approach is commonly associated 
with modest and often transient weight loss, rarely exceeding 10% 
of body weight.4 Pharmacotherapies have been developed to use in 
conjunction with lifestyle modification to facilitate successful weight 
loss. In more severe cases of obesity, bariatric surgery may be recom-
mended. Recent advances in the molecular mechanisms regulating 
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Abstract
Obesity and type 2 diabetes are key healthcare challenges of the 21st century. 
Subsequent to its discovery in 1948, serotonin (5- hydroxytryptamine; 5- HT) has 
emerged as a principal modulator of energy homeostasis and body weight, prompt-
ing it to be a target of weight loss medications (eg, fenfluramine, D- fenfluramine, 
fenfluramine- phentermine and sibutramine). The potential risk of off- target effects 
led to these medications being withdrawn from clinical use and spurred drug discov-
ery into 5- HT receptor selective ligands. The serotonin 2C receptor (5- HT2CR) is the 
primary receptor through which 5- HT impacts feeding and body weight and 5- HT2CR 
agonist lorcaserin was released for obesity treatment in 2012. Obese patients with 
type 2 diabetes prescribed medications that produce weight loss commonly observe 
improvements in type 2 diabetes. However, recent research has provided compel-
ling evidence that 5- HT2CR agonists produce effects on blood glucose and insulin 
sensitivity independent of weight loss. As such, neuroactive 5- HT2CR agonists are a 
potential new category of type 2 diabetes medications. 5- HT is also expressed within 
pancreatic β cells, is co- released with insulin and may have a role in modulating insulin 
secretion. This review highlights the latest advances in the function of 5- HT in body 
weight, insulin release and glycaemic control.
K E Y W O R D S
5- HT, body weight, glycaemic control, insulin, obesity, serotonin
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2021 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of British Society for Neuroendocrinology
2 of 12  |     GEORGESCU Et al.
satiety and energy homeostasis have provided new targets for drug 
discovery for obesity treatment. The brain has emerged as the mas-
ter orchestrator of food intake and energy balance, integrating func-
tionally relevant signals within pathways and regulatory nodes to 
exert coordinated control of whole body metabolism. Accumulating 
evidence over the past decade has also revealed a role for the brain 
in glycaemic control.
The focus of this review is serotonin (5- hydroxytryptamine; 
5- HT), which is a key modulator of food intake and energy me-
tabolism and a target of weight loss medications (eg, fenfluramine, 
D- fenfluramine, fenfluramine- phentermine, sibutramine and lorca-
serin). Obese patients with type 2 diabetes prescribed medications 
that produce weight loss commonly observe improvements in type 
2 diabetes. Recent evidence indicates that 5- HT weight loss med-
ications also directly improve type 2 diabetes without weight loss 
by reducing hepatic glucose production and increasing insulin sen-
sitivity. 5- HT is also expressed within the pancreatic β cells, being 
co- released with insulin, and may have a role in modulating insulin 
secretion. These topics are discussed below.
2  | 5- HT SYNTHESIS
The synthesis of the monoamine transmitter 5- HT is carried out in 
a two- step process that requires the essential dietary amino acid 
tryptophan. The first step involves the conversion of tryptophan to 
5- hydroxytryptophan. Tryptophan hydroxylase catalyses this reac-
tion and is the rate- limiting enzyme for the pathway.5 There are two 
isoforms of this enzyme: tryptophan hydroxylase 1 (Tph1) expressed 
in peripheral tissues and Tph2 expressed in the brain.6 In the sec-
ond and final step, aromatic l- amino acid decarboxylase converts 
5- hydroxytryptophan into 5- HT.
5- HT has a broad range of physiological and behavioural func-
tions and is present in most species. In mammals, 5- HT is synthe-
sised in both the periphery and the central nervous system (CNS). In 
the periphery, 5- HT is primarily produced by enterochromaffin cells 
of the gastrointestinal tract where it regulates intestinal motility.7 
5- HT has also been reported in other organs and tissues and has 
been linked to the function of brain, liver, bone, mammary glands 
and pancreatic β cells.8- 10
3  | 5- HT RELE A SE AND METABOLISM
Once synthesised, 5- HT is stored in vesicles and released 
through regulated exocytosis allowing it to bind to 5- HT recep-
tors (Figure 1). The 5- HT transporter (5- HTT or SERT) is respon-
sible for the reuptake of 5- HT. Metabolism of 5- HT is carried out 
in two steps, with the first being oxidative deamination by mono-
amine oxidase A, yielding 5- hydroxyindole- 3- acetaldehyde. In the 
second step, aldehyde dehydrogenase catalyses the oxidation of 
5- hydroxyindole- 3- acetaldehyde to 5- hydroxyindoleacetic acid.
F I G U R E  1   Serotonin 
(5- hydroxytryptamine; 5- HT) synthesis 
and neuronal signalling. 5- HT is 
synthesised in the presynaptic neurone 
from the amino acid tryptophan. 
Following activation of this neurone, 5- HT 
is packed into vesicles and released into 
the synaptic cleft, where it signals through 
its receptors (5- HT1R to 5- HT7R). The 
signalling is terminated by re- uptake of 
5- HT from the cleft by 5- HT transporter 
(5- HTT). AC, adenylate cyclase; 
DAG, 1,2- diacylglycerol; IP3, inositol 
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4  | 5- HT RECEPTORS
Beginning in the 1950s, numerous 5- HT receptors have been dis-
covered in mammals.11 Following their discovery, some receptors 
have been renamed. 5- HT receptors are now grouped into seven 
families (5- HT1R to 5- HT7R) based on sequence homology and in-
tracellular effectors (Figure 2). The change in receptor nomenclature 
highlights the importance of the awareness of earlier names of a sin-
gle receptor when reading and interpreting earlier reports. 5- HT3Rs 
are ligand gated cation channels. All the other 5- HT receptors com-
prise a G- protein coupled with an extracellular N- terminus, seven 
transmembrane domains connected by three extracellular and three 
intracellular loops, and an intracellular C- terminus.11,12 All 5- HT re-
ceptors are expressed postsynaptically. All 5- HT receptors are ex-
pressed in both the brain and periphery to varying degrees, with the 
following exceptions: 5- HT2CRs and 5- HT6Rs are predominantly, if 
not exclusively, expressed within the CNS, whereas 5- HT2BRs are 
primarily expressed in the periphery.13
Receptors within the 5- HT1 family are Gi/o- coupled and may also 
be positioned as autoreceptors and heteroreceptors. 5- HT5Rs are 
also Gi/o- coupled and function to hyperpolarise cells. The 5- HT4R, 
5- HT6R and 5- HT7R families are Gs- coupled and their activation 
results in cell depolarisation. 5- HT2Rs couple to Gq/11. In addition 
to these canonical signalling pathways, recent evidence suggests 
that metabotropic 5- HT receptors also signal through a variety of 
non- canonical pathways.11 This is worth considering when predict-
ing a cellular response following 5- HT receptor activation. 5- HT re-
ceptors are similarly distributed in vertebrates, with the following 
exceptions: rodents do not have 5- ht1eRs, humans do not express 
full- length 5- ht5bRs, and humans and rodents exhibit a different pat-
tern of 5- HT3R and 5- HT6R distribution within the forebrain.
11 5- 
ht1eR and 5- ht5bR are denoted with lower case appellation because a 
F I G U R E  2   Serotonin (5- hydroxytryptamine; 5- HT) receptor discovery and nomenclature. 5- HT receptors were first discovered in the 
1950s and designated D and M. Subsequently, additional receptors have been identified and the receptors have been grouped into seven 
families based on sequence homology and effector pathways. Currently, 14 5- HT receptors have been identified in mammals. Adapted from 
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functional response in native cells has not yet been demonstrated.13 
Isoforms of 5- HT2CRs, 5- HT3Rs, 5- HT4Rs and 5- HT7Rs have been 
identified, although the specific function of these isoforms remains 
to be clearly established. 5- HT2CRs are the only 5- HTR that undergo 
RNA editing.
5  | β  CELL 5-  HT
5.1 | 5- HT and receptor expression
Evidence of 5- HT in the pancreatic islets of Langerhans dates to 
studies carried out more than 50 years ago.14 β cells co- release 5- HT 
alongside insulin and ATP.15,16 Expression of tryptophan hydroxy-
lase (TPH1) in β cells indicates the capacity for de novo synthesis 
of 5- HT in the islets of Langerhans.17- 19 Mice lacking TPH1 only in 
β cells are glucose intolerant and secrete less insulin when fed a 
high- fat diet for 6 weeks.20 This link is specific to β cells because 
TPH1 knockout in gut enterochromaffin cells does not affect insu-
lin secretion.21,22 Human and rodent β cells also express 5- HTT, the 
transporter responsible for 5- HT reuptake.17,19 Research suggests 
that 5- HT acts as an autocrine signal modulating β cell function and 
proliferation20,23- 25 (Figure 3).
The presence of 5- HT1ARs, 5- HT1DRs, 5- HT1FRs, 5- HT2BRs, 5- 
HT3Rs and 5- HT5ARs within human islets has been revealed via a 
revealed via gene and/or protein expression techniques.19,25,26 
Different receptors appear to be primarily expressed within specific 
cell types, with 5- HT1ARs, 5- HT1DRs, 5- HT2BRs and 5- HT3Rs in β 
cells, 5- HT1FRs in α cells, and 5- HT5ARs in δ cells.
19,25,26
5.2 | Insulin secretion and β cell proliferation
5- HT2BR agonists promote insulin secretion, an effect partly regu-
lated by a rise in intracellular [Ca2+] and enhanced mitochondrial 
activity.25 Expression of 5- HT2BRs in mouse islets increases during 
pregnancy and it serves to enhance β cell proliferation during this 
period of high insulin demand.23 Pharmacological inhibition of the 
5- HT2BR impaired glucose tolerance and reduced the pregnancy- 
associated increase in β cell mass, highlighting this receptor as 
a favourable target for the treatment of gestational diabetes.23 
Regulation of insulin secretion and β cell function has also been 
described during lactation, and this phenomenon is dependent 
on 5- HT signalling at the 5- HT2BR.
27 However, mice with a β cell- 
specific knockout of 5- HT2BRs are not glucose intolerant after a 
6- week period of high- fat diet, whereas 5- HT3R knockout mice 
display diminishes glucose- stimulated insulin secretion.20 Glucose- 
dependent 5- HT release from human β cells also acts on α cells to in-
hibit glucagon secretion via action at the 5- HT1FR.
19 Administration 
of a 5- HT1FR agonist lowered glucagon secretion and improved gly-
caemic levels in diabetic mice.19 These findings suggest that pan-
creatic 5- HT plays a significant role in insulin secretion via action at 
different 5- HT receptors expressed on distinct cell types.20,23
In addition to receptor- mediated transductional processes, 
receptor- independent 5- HT signalling may also influence insulin 
secretion. For example, non- canonical transductional mechanisms 
promote insulin exocytosis from β cells via serotonylation of Rab 
proteins.21 As demonstrated in other tissues, serotonylation relies 
on transamination by transglutaminases of 5- HT to small GTPases 
resulting in these being constitutively active.28 Further supporting 
this receptor- independent effect of 5- HT, transglutaminase 2 null 
mice are glucose- intolerant and show decreased levels of insulin 
following glucose stimulation.29 Walther et al28 propose a dynamic 
model in which progressive insulin and 5- HT co- secretion promotes 
high extracellular 5- HT concentrations that, via an autocrine feed-
back loop, attenuates additional insulin (and 5- HT) release through 
inhibitory 5- HT1ARs located on β cells. Extracellular 5- HT is subse-
quently cleared via 5- HTT. They propose that as extracellular 5- HT 
levels fall and intracellular 5- HT levels build, insulin (and 5- HT) se-
cretion is once more enhanced via serotonylation (Figure 3).
Although 5- HT was identified in the islet more than half a cen-
tury ago, the physiological function of 5- HT co- release with insulin 
is still largely unknown. Seemingly contradictory reports may be 
reconciled by differing functions of distinct 5- HT receptors in dif-
ferent cell types and receptor- independent 5- HT action. Additional 
research is required to clarify the function of 5- HT in the islet and in 
the modulation of insulin secretion.
6  | BR AIN 5-  HT
6.1 | 5- HT and receptor expression
Although comparatively little is known about the function of 5- HT 
in pancreatic insulin secretion and β cell proliferation, more intense 
research efforts have focussed on the role of 5- HT in the brain. CNS 
5- HT influences a wide variety of processes, such as energy balance, 
anxiety, mood, migraine, sleep, locomotion, circadian rhythms and 
aggression, amongst others. This review is focussed on the role of 
CNS 5- HT in the modulation of feeding behaviour, body weight and 
glycaemic control.
5- HT synthesis requires the essential amino acid tryptophan 
obtained from food. Tryptophan is carried by an active transport 
mechanism into the brain where it is converted into 5- HT. Because 
tryptophan competes with the other large neutral amino acids (LNAA) 
for transport into the brain, the ratio of tryptophan to other LNAA is 
an important determinant for 5- HT synthesis.30 Peripherally derived 
5- HT does not cross the blood- brain barrier. However, recent stud-
ies reveal the presence of 5- HTT in the brain endothelium and have 
linked this to transport of augmented 5- HT from the brain into the 
blood, but not vice- versa.31- 33 Brain 5- HT is produced in a collection 
of midline brainstem nuclei called raphe, meaning a ‘seam connect-
ing two halves’. The raphe nuclei are comprised of the raphe pallidus 
(RPa; B1), raphe obscurus (ROb; B2), raphe magnus (RMg; B3), raphe 
pontis (RPn; B4), median raphe (RMn; B5, B8), dorsal raphe (DRN; 
B6, B7) and the supralemniscal nucleus (SLN; B9). Unlike the other 
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raphe nuclei, the SLN is not expressed on the midline. These nuclei 
were previously designated B1- B9 and project to distinct parts of 
the brain such that almost all brain regions are innervated by 5- HT 
terminals to some extent. The cluster of caudal raphe nuclei (B1- B4) 
are responsible for descending 5- HT projections that innervate re-
gions including the cerebellum, midbrain, pons, medulla and spinal 
F I G U R E  3   Schematic of model of exocytosis of β granules from β cells in response to serotonin (5- hydroxytryptamine; 5- HT). Glucose 
(Glu) is transported into the cell, oxidised by the mitochondria to produce ATP, which then causes the closure of the KATP channel and leads 
to depolarisation of the membrane. This opens the voltage- dependent Ca2+ channel and the influx of Ca2+ ions activate transglutaminase 
(TGases) and serotonylate a number of proteins. Amongst these, Rab3a and Rab27a are essential for insulin release. Thereby their activation 
causes co- secretion of 5- HT and insulin. By signalling at the 5- HT1AR, high extracellular 5- HT ([5- HT]e) reduces further secretion of 
insulin. However, this effect is dampened as 5- HT reuptake occurs via the 5- HT transporter (5- HTT). When intracellular 5- HT ([5- HT]i) 
is substantially higher than extracellular 5- HT ([5- HT]e), this triggers another event of insulin secretion by serotonylation. This dynamic 
regulation of 5- HT levels may explain the established oscillation of insulin exocytosis from glucose stimulated β cells. Adapted from 
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cord, whereas the more rostral raphe nuclei (B5- B9) give rise to as-
cending projections that target areas such as the cortex, hippocam-
pus, thalamus, hypothalamus, striatum and amygdala34- 37 (Figure 4). 
The DRN is the largest raphe nuclei and distinct DRN subdivisions 
are relevant to energy homeostasis.34 The arcuate nucleus of the 
hypothalamus (ARC) melanocortin pro- opiomelanocortin (POMC) 
and agouti- related peptide (AgRP) neuronal populations are primary 
regulators of energy homeostasis and are innervated by 5- HT fi-
bres.36,38- 41 The melanocortin system is required for 5- HT weight 
loss medications to produce their therapeutic effect.42- 47
6.2 | Food intake and body weight
Early research with 5- HT revealed a strong inverse relationship be-
tween 5- HT and food intake. Although brain 5- HT accounts for a 
relatively small percentage of 5- HT (approximately 3%), research in 
the 1970s revealed that brain 5- HT is necessary for normal appetite 
and body weight regulation. Specifically, in back- to- back publica-
tions in Science in 1976, both Breisch et al48 and Saller and Stricker49 
reported that selectively decreasing brain 5- HT synthesis promoted 
weight gain and the development of obesity. Early pharmacological 
strategies to elevate brain 5- HT to treat obesity selectively blocked 
5- HT reuptake (selective serotonin reuptake inhibitor; SSRI) and 
stimulated 5- HT release.
7  | CLINIC AL AND PRECLINIC AL 5-  HT 
MEDIC ATIONS
7.1 | Medications augmenting 5- HT bioavailability
7.1.1 | Fenfluramine,	D- fenfluramine and 
fenfluramine- phentermine (fen- phen)
Medications specifically targeting 5- HT for obesity treatment were 
fenfluramine (Pondimin) and the D- enantiomer of fenfluramine (D- 
fenfluramine, dexfenfluramine, Redux), which stimulate the release of 
5- HT and block its reuptake. Fenfluramine and D- fenfluramine alone 
and in combination with phentermine (fen- phen) were used to treat 
human obesity until the late 1990s when they were withdrawn from 
clinical use as a result of valvular side effects in a small group of obese 
patients.50 Earlier this year, the US Food and Drug Administration 
(FDA) and European Medicines Agency granted or recommended 
granting the marketing of fenfluramine (Fintepla) for the treatment of 
seizures associated the severe form of epilepsy Dravet syndrome.
F I G U R E  4   Schematic of raphe nuclei localisation and selected projections. 5- HT neurones within the raphe nuclei cluster along the 
midline and broadly innervate the CNS. Displayed is a schematic of a sagittal midline brain view illustrating the relative localisation of the 
raphe nuclei and some selected projections. 3V, third ventricle; 4V, fourth ventricle; ACC, anterior cingulate cortex; Aq, aqueduct; ARC, 
arcuate nucleus of the hypothalamus; BNST, bed nucleus of the stria terminalis; RPa, raphe pallidus nucleus, B1; ROb, raphe obscurus 
nucleus, B2; RMg, raphe 2magnus nucleus, B3; RPn, raphe pontis nucleus, B4; RMn, median raphe nucleus, B5, B8; DRN, dorsal raphe 
nucleus, B6, B7; SLN, supralemniscal nucleus, B9; FC, frontal cortex; NAcc, nucleus accumbens; NTS, nucleus of the solitary tract; PAG, 
periaqueductal grey; PVH, paraventricular hypothalamic nucleus; SC, spinal cord; V1, primary visual cortex; and VTA, ventral tegmental area 
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The primary therapeutic mechanism of fenfluramine and D- 
fenfluramine in treating obesity is achieved via decreasing food in-
take.51 However, some evidence suggests that D- fenfluramine may 
also increase resting and postprandial energy expenditure in obese 
patients.52 Fenfluramine was also found to have effects on glucose 
tolerance. For example, following a 7- day treatment with fenflu-
ramine, blood glucose of obese patients with type 2 diabetes was 
significantly lowered.53 The glycaemic effect may be at least in part 
independent of the anorexigenic effects of fenfluramine.53- 55
Following the withdrawal of fenfluramine, D- fenfluramine and 
fen- phen for weight loss, research effort turned to establishing 
the receptors underpinning both the off- target and therapeutic 
effects. The receptor implicated in the adverse effect is peripheral 
5- HT2BRs. Compelling evidence indicating that brain 5- HT2CRs are 
required for the therapeutic effect was provided by transgenic 
mouse studies. Specifically, 5- HT2CR knockout mice do not re-
spond to the anorectic effect of D- fenfluramine.42,56 Given that 
the 5- HT2CRs are expressed in a variety of brain regions where 
they produce an array of behavioural effects, additional studies 
aimed to define the specific subset of 5- HT2CRs and the circuit 
through which D- fenfluramine reduces feeding. 5- HT2CRs are co- 
expressed with ARC POMC neurones and D- fenfluramine and 5- 
HT2CR agonists increase POMC neurone activity.
47 In mice null 
for 5- HT2CRs, re- expression of 5- HT2CRs only in POMC neurones 
restored the anorectic effect of D- fenfluramine.42 Illustrating the 
necessity of POMC peptides the effect of D- fenfluramine on food 
intake, pharmacological (SHU9119) or genetic (Mc4r null mice) 
blockade of one of the receptor targets for POMC peptides, the 
melanocortin4 receptor (MC4R), attenuated the effects of D- 
fenfluramine.42,47 The circuit was further clarified through trans-
genic MC4R re- expression, which revealed that MC4Rs within the 
paraventricular nucleus of the hypothalamus (PVH) are sufficient 
for D- fenfluramine food intake suppression.42 In summary, a key 
mechanism through which D- fenfluramine decreases feeding is 
via activation of the subset of 5- HT2CRs co- expressed with ARC 
POMC, which stimulates the release of POMC peptides to act at 
MC4Rs within the PVH.
7.1.2 | Sibutramine
Sibutramine (Meridia) is a 5- HT and noradrenaline reuptake inhibi-
tor that was prescribed for obesity treatment between 1997 and 
2010 and typically produced 5%- 7% weight loss.57,58 Patient stud-
ies indicate that the anorectic effects of sibutramine are main-
tained during 10 months of treatment.59 However, sibutramine 
was withdrawn from clinical use in 2010 as a result of reports as-
sociating it with increased risk of myocardial infarction and stroke 
in obese patients.60
Similar to fenfluramine, sibutramine decreases feeding and 
enhances satiety.59 In rats, it has also been reported to exert ef-
fects on energy expenditure61; however, in humans, the effect 
on energy expenditure is not apparent. Weight loss is typically 
associated with a lowering of energy expenditure. Although one 
study reported that sibutramine partially attenuated the decline in 
energy expenditure with weight loss in obese people (P = 0.09),62 
other studies report no effect of sibutramine on energy expen-
diture in people.63,64 Alongside its anorectic effects, sibutramine 
action also improves glycaemic control in obese people with 
type 2 diabetes.58 A randomised prospective placebo- controlled 
double- blinded study in patients with type 2 diabetes prescribed 
metformin indicated that patients treated with sibutramine 
showed significant weight loss and improved glycaemic control, 
and demonstrated fasting blood glucose in parallel with weight 
loss over the 12- month period.65 Sibutramine treated patients also 
had reduced levels of A1c (HbA1C), a glycated form of haemoglo-
bin that is used as a clinical biomarker for diabetes.65 Similar to 
D- fenfluramine, 5- HT2CRs and POMC are implicated in the obesity 
therapeutic effect of sibutramine.43,66,67
Medications broadly increasing 5- HT bioavailability are ef-
fective for treating human obesity and commonly improve insu-
lin sensitivity and glycaemic control in obese patients with type 
2 diabetes by promoting weight loss. However, the risk of off- 
target effects was deemed to outweigh the therapeutic benefit 
of fenfluramine, D- fenfluramine, fen- phen and sibutramine and 
they were subsequently withdrawn from human treatment. Other 
SSRIs are still commonly prescribed for conditions such as anxi-
ety and depression (eg, fluoxetine/Prozac). Obesity increases the 
risk of heart disease and stroke. This suggests that a subset of 
obese people with increased risk of heart disease and stroke may 
be more susceptible cardiovascular complications associated with 
5- HT medications.
Genetic and pharmacological research indicate that the ther-
apeutic effect of fenfluramine, D- fenfluramine and sibutramine 
is primarily achieved via 5- HT action at brain 5- HT2CRs and this 
spurred drug discovery efforts toward the development of selective 
5- HT2CR agonists. Of the 5- HT receptors, only 5- HT2CR null mice ex-
hibit hyperphagia and obesity and develop characteristics of type 2 
diabetes.68,69 5- HTR knockout studies also highlight the importance 
of the 5- HT2BRs in cardiac structure and function.
70 The only 5- HT 
receptor that is fatal if knocked out in mice is the 5- HT2BR.
71 Thus, 
a challenge during this drug discovery period was to develop a com-




Preclinical meta- chlorophenylpiperazine (mCPP) provided some of 
the first insights into the potential of a 5- HT2CR agonist for obesity 
treatment. However, this compound was unlikely to be suitable for 
widespread human use because it has affinity for multiple recep-
tors in addition to the 5- HT2CR (pEC50 7.00), including the 5- HT2BR 
(pEC50 7.2). Similar to former 5- HT weight loss medications, mCPP 
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reduces food intake and body weight in rodents 72 and humans.73 
This effect appears to be primarily achieved via the 5- HT2CRs given 
that mCPP does not reduce feeding in mice lacking 5- HT2CRs.
68
The first clear indication of the potential of 5- HT medications 
in the direct improvement of glycaemic control was observed with 
mCPP. In a dietary- induced obese mouse model of type 2 diabe-
tes, a single treatment with mCPP rapidly improved glucose and 
insulin tolerance over the next 2 hours.74 Significant improve-
ments in glycaemia were achieved at doses of mCPP that were 
too low to reduce feeding. Specifically, improvements in glycae-
mia were achieved at 1 mg/kg, whereas more than double of this 
dose (2.5 mg/kg) was required to impact feeding behaviour. A sin-
gle pre- treatment of mCPP prior to a bolus of insulin also signifi-
cantly increased insulin sensitivity in muscle and liver.74 Similarly, 
prolonged treatment with mCPP improved glucose and insulin 
tolerance, reduced hyperinsulinaemia and decreased enzymes 
associated with hepatic glucose production.74 These beneficial 
effects were achieved at a dose of mCPP that was too low to im-
pact feeding or body weight.74 These findings illustrated the first 
dissociation between the effects of a 5- HT drug on appetite/body 
weight and glycaemic control/insulin sensitivity.
Research investigating the mechanism of action of mCPP and 
other preclinical 5- HT2CR agonists (eg BVT.X and WAY161,503) on 
appetite and glycaemic control/insulin sensitivity also point to the 
melanocortin system. WAY161,503 increases the activity of ARC 
POMC neurones.43 Similarly, mCPP increases the activity of ARC 
POMC cells and this is achieved via a postsynaptic mechanism reli-
ant on the presence of TRPC channels.47,75 Illustrating the necessity 
of the subset of 5- HT2CRs specifically in POMC neurones, mCPP 
does not impact feeding in mice selectively lacking 5- HT2CRs only 
in POMC neurones.76 D'Agostino et al44 revealed that POMC pep-
tides are required for the complete anorectic effect of WAY161,503 
using both a transgenic knockout and a brain region selective Pomc 
CRISPR/Cas9 knockdown approach in mice. Similarly, BVT.X is inef-
fective at reducing food intake in MC4R knockout mice.77
As noted above, whole brain 5- HT2CR knockout mice exhibit 
obesity and parameters associated with type 2 diabetes (eg, insu-
lin resistance and impaired glucose tolerance).60 On a high- fat diet, 
5- HT2CR knockout mice also develop hyperglycaemia.
60 Selectively 
knocking out 5- HT2CRs only in POMC neurones does not promote 
obesity, but does cause hyperinsulinaemia, hyperglycaemia, hy-
perglucagonaemia and insulin resistance.76 These findings provide 
further evidence that 5- HT2CRs play a key role in glycaemic con-
trol independently of their established effect on appetite and body 
weight. Pharmacologically or genetically blocking one of the down-
stream receptor targets of POMC peptides, the MC4R, prevents the 
effects of mCPP on glycaemic control and insulin sensitivity.74
These preclinical findings highlighted the potential for a 5- HT2CR 
agonist for the treatment of both obesity and type 2 diabetes and 
indicate that both effects are achieved via the melanocortin system. 
Follow- up research with 5- HT2CR agonist lorcaserin, as described 
below, reveals the different branches of melanocortin circuitry pro-
ducing these effects.
7.2.2 | Weight	loss	medication	lorcaserin
The USA FDA approval of the selective 5- HT2CR agonist lorcaserin 
in 2012 represented the first weight loss medication approved by 
the FDA in over a decade. Lorcaserin is a full agonist at the 5- HT2CR, 
where it exhibits 104- fold selectivity over the 5- HT2BR.
78 Lorcaserin 
improves obesity by reducing food intake.44,45,78,79 It does not alter 
energy expenditure.80 In addition to homeostatic feeding, lorcaserin 
also decreases operant responding for food reward, impulsivity and 
binge eating.81- 84 In clinical trials, lorcaserin reduced body weight by 
approximately 5% in obese patients.85- 87 Lorcaserin's weight loss is 
characterised by a reduction of fat mass but not lean mass.78 In an-
other study, lorcaserin treatment led a reduction in central adiposity 
compared to placebo.88 Trunk fat mass has been associated with a 
higher risk of obesity- associated comorbidities such as cardiovascu-
lar diseases, further highlighting the potential benefits of lorcaserin 
treatment. These cardiometabolic health improvements associated 
with lorcaserin treatment have been shown to be dependent on a 
reduction in total atherogenic lipoproteins.89 A large scale, 5- year 
cardiovascular analysis was performed in the CAMELLIA- TIMI 61 
trial described below.
Lorcaserin produces an improvement in glycaemic control in 
mouse models of type 2 diabetes independent of weight loss.45 
Indeed, the doses of drug required to improve glycaemia (4 mg/
kg) were approximately half that required to decrease food intake 
(7.5 mg/kg).45 These benefits of lorcaserin were achieved via reduc-
ing hepatic glucose production and increasing insulin sensitivity.45 
Lorcaserin does not appear to influence insulin secretion in mice.45 
Demonstrating the translational potential of lorcaserin for the treat-
ment of type 2 diabetes, clinical trials in obese patients with type 2 
diabetes revealed that lorcaserin improved HbA1C levels and fast-
ing glucose levels86 irrespective of the weight loss.90 Data obtained 
from the approximately 12,000 patient CAMELLIA- TIMI 61 trial in-
dicated that lorcaserin significantly reduced the risk of developing 
diabetes by 23% in participants without prediabetes or diabetes and 
by 19% in participants with prediabetes.91 In participants with dia-
betes, lorcaserin significantly lowered HbA1C and the risk of diabetic 
microvascular complications.91
Analysis of the mechanism of action revealed that lorcaserin re-
quires POMC to produce its effects on food intake.44 Similalrly, the 
glucoregulatory effects of lorcaserin are absent in brain Pomc null 
mice, but the specific re- expression of Pomc only in 5- HT2CRs neu-
rones is sufficient to restore the glycaemic actions of lorcaserin.45 
The effects of lorcaserin on food intake, glycaemia and insulin sen-
sitivity require downstream MC4Rs.45 The effects on glycaemia and 
insulin sensitivity, but not food intake, require the specific subset of 
MC4Rs expressed in preautonomic cholinergic neurones in the dor-
sal vagal complex and spinal cord.45 These data illustrate the disso-
ciation of the circuitry through which lorcaserin modulates appetite 
and blood glucose/insulin sensitivity.
With regards to safety, the FDA requested a long- term trial eval-
uating the potential cardiovascular effects of lorcaserin as part of a 
postmarketing requirement. The CAMELLIA- TIMI 61 trial comprised 
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a 5- year, randomised, double- blind, placebo controlled, multicentre 
trial using 473 sites in eight countries. Involving approximately 
12,000 overweight or obese patients with atherosclerotic cardiovas-
cular disease or multiple cardiovascular risk factors, CAMELLIA- TIMI 
61 comprises the largest cardiovascular outcome study for a weight 
loss medication to date. No significant differences between treat-
ment groups were seen for any major adverse events.92,93 Rather, 
lorcaserin promoted significant weight loss and provided further 
health benefits, decreasing the risk of the development of diabetes 
and improving diabetes and diabetic microvascular complications in 
participants with type 2 diabetes.92,93 In a decision that is difficult 
to interpret, in 2020, the FDA concluded that the potential risks of 
lorcaserin outweigh its benefits. Despite the finding that lorcaserin 
did not increase the incidence of any serious adverse events, the 
FDA focussed on a small numerical difference in the incidence of 
malignancies during the CAMELLIA- TIMI 61 trial: 7.7% of lorcaserin 
treated patients compared to 7.1% of placebo treated patients were 
diagnosed with some form of cancer over the 5- year period. Given 
that obesity is established to increase the risk of cancer (by approxi-
mately 7.1% over 5 years as suggested by the placebo- treated group) 
and that there was no statistical difference between the lorcaserin 
and placebo groups with respect to the incidence of malignancies, 
the FDA’s interpretation of the similar rates of malignancies over 
the 5 year monitoring period is difficult to understand. The man-
ufacturer of lorcaserin, Eisai, voluntarily withdraw lorcaserin from 
the USA market for obesity treatment in February 2020. However, 
lorcaserin is still marketed in other countries for obesity and, in 
consultation with the FDA, lorcaserin is entering into a phase 3 trial 
(MOMENTUM 1) for Dravet syndrome, a severe form of epilepsy 
that first presents in infancy. Mice lacking 5- HT2CRs are prone to 
seizures that can be fatal,68 providing a rationale that a 5- HT2CR ag-
onist could be effective for treating seizures associated with Dravet 
syndrome.
In summary, 5- HT2CR agonists are effective at improving obesity 
and show therapeutic benefit with respect to glycaemic control and 
insulin sensitivity in obese individuals with prediabetes or type 2 di-
abetes. Lorcaserin is also effective at reducing the onset of new type 
2 diabetes. These effects on diabetes parameters are not dependent 
upon weight loss, indicating a parallel mechanism of action. Current 
frontline diabetes medications target peripheral tissues to produce 
a therapeutic benefit. Thus, these findings with 5- HT2CR agonists 
represent a first indication that the brain may be harnessed to im-
prove type 2 diabetes in humans. Lorcaserin reduces body weight 
by promoting satiety and also decreases motivation for food reward 
and impulsivity.81,82,94 It is therefore perhaps surprising that the ef-
fects on body weight are not larger. 5- HT2CRs are subjected to RNA 
editing events in which adenosine deaminase converts adenosine 
residues to inosines. These post- transcriptional modifications can 
impact the efficacy of receptor to G- protein coupling, suggesting 
an additional mechanism by which 5- HT signal transduction is reg-
ulated.95 In a genetically engineered mouse line, increased 5- HT2CR 
RNA editing attenuated the anorectic effect of 5- HT2CR agonist 
WAY161,503.96 It is therefore possible that 5- HT2CR RNA editing 
may impact the efficacy of 5- HT2CR medications in patients. This 
possibility remains to be investigated.
8  | CONCLUSIONS
Obesity and type 2 diabetes are currently a growing global health 
concern. The brain, acting as the principal orchestrator of feeding 
behaviours, hosts a complex array of networks regulating energy 
homeostasis. Key amongst these are 5- HT circuits and, correspond-
ingly, various therapeutics target components of this system, par-
ticularly the 5- HT2CRs. Weight loss commonly improves type 2 
diabetes and, as such, 5- HT obesity drugs would be expected to im-
prove glycaemic control and insulin sensitivity in patients with type 
2 diabetes. However, recent research has provided compelling evi-
dence that 5- HT2CR agonists produce effects on blood glucose and 
insulin sensitivity independently of weight loss. As such, this opens 
up a potentially new category of type 2 diabetes medications, com-
prising a class of drugs that target the brain.
Early 5- HT weight loss medications (fenfluramine, D- fenfluramine 
and sibutramine) alter whole body 5- HT bioavailability and therefore 
influence multiple 5- HT receptors, including those not directly in-
volved in the regulation of ingestive behaviour and metabolism. Side 
effects led to their withdrawal and the emergence of the selective 
5- HT2CR agonist lorcaserin. Lorcaserin directly targets the principal 
5- HT receptor influencing body weight. The therapeutic efficacy 
of lorcaserin is associated with an improved side effect profile at-
tributed to lack of agonism at the 5- HT2BR.
85 The clinical utility of 
medications such as lorcaserin has nonetheless highlighted the need 
to further understand the mechanisms through which their benefi-
cial effect is achieved. Research indicates that lorcaserin requires 
melanocortin pathways to reduce food intake and improve glycae-
mic control/insulin sensitivity. Principal MC4Rs controlling feeding 
reside within the paraventricular nucleus of the hypothalamus,97,98 
whereas MC4Rs controlling the effects of lorcaserin on glycaemia 
and insulin sensitivity reside in the brainstem and spinal cord.45
Current weight loss medications and those in clinical trials com-
bine different ligands to produce a greater therapeutic effect (eg, 
contrave: bupropion and naltrexone; quismia: phentermine and 
topiramate; and various emerging gut peptide combinations). Thus, 
another future strategy to improve the therapeutic profile of lor-
caserin is combination therapy. 5- HT1BR agonists CP- 94253 and 
RU- 24969 promote food intake reductions and this effect is blocked 
by pre- treatment with the 5- HT1BR antagonists.
40,99 Combined ad-
ministration of sub- anorectic doses of 5- HT1BR and 5- HT2CR ago-
nists results in a synergistic reduction in food intake in mice100 and 
rats.101 5- HT1BRs are primarily expressed as heteroreceptors on 
non- 5- HT terminals, where they prevent the release of other neu-
rotransmitters. Evidence suggests that a key mechanism underpin-
ning the anorectic effects of 5- HT1BRs is via hyperpolarisation of 
AgRP neurones and the resultant reduction in the inhibitory tone 
onto ARC POMC neurones.40,100 The combination of 5- HT1BR and 
5- HT2CR agonists thereby increases the absolute number of POMC 
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neurones activated compared to each agonist administered alone 
and this results in a correspondingly greater reduction in food in-
take.102 Whether this combination also increases the effects of lor-
caserin on glycaemic control and insulin sensitivity has not yet been 
reported. These findings illustrate the potential of a combination of 
a 5- HT2CR agonist with other anorectic ligands to produce an im-
proved therapeutic profile.
Compelling genetic, pharmacological and anatomical evidence 
generated over the last half century points to the 5- HT system as 
having a key role in the regulation of energy homeostasis and in 
insulin secretion from β cells. Brain 5- HT via action at 5- HT2CRs 
impacts feeding, body weight, glycaemic control and insulin sensi-
tivity. Pancreatic 5- HT is co- secreted from β cells where it acts at 
5- HT1ARs, 5- HT1FRs and 5- HT2BRs to influence insulin secretion. 
The mechanisms through which 5- HT modulates insulin sensitivity 
and insulin release are still not well understood and provide an excit-
ing opportunity for future research.
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